| Deborah Marie Rambo, CRNA | |
|
809 82nd Pkwy, Anesth Dept, Myrtle Beach, SC 29572-4607 | |
| (843) 692-1000 | |
| Not Available |
| Full Name | Deborah Marie Rambo |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 32 Years |
| Location | 809 82nd Pkwy, Myrtle Beach, South Carolina |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043270184 | NPI | - | NPPES |
| AN1133 | Medicaid | SC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 158 (South Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Grand Strand Regional Medical Center | Myrtle beach, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Atlantic Coast Anesthesia Services Pc | 3971887167 | 90 |
News Archive
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead product MycAssay™ Aspergillus for detection of Aspergillus DNA in serum.
Historically, health insurance covered mental health care differently than other medical care. Recent laws have begun bringing them into balance. ... Congress passed the Mental Health Parity and Addiction Equity Act (MHPAEA) in 2008. ... the MHPAEA applied to large group health plans, both fully and self-insured, and included a cost exemption.
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
› Verified 2 days ago
| Entity Name | Man In The Box Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760462378 PECOS PAC ID: 2567376809 Enrollment ID: O20031119000444 |
News Archive
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead product MycAssay™ Aspergillus for detection of Aspergillus DNA in serum.
Historically, health insurance covered mental health care differently than other medical care. Recent laws have begun bringing them into balance. ... Congress passed the Mental Health Parity and Addiction Equity Act (MHPAEA) in 2008. ... the MHPAEA applied to large group health plans, both fully and self-insured, and included a cost exemption.
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
› Verified 2 days ago
| Entity Name | Atlantic Coast Anesthesia Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932641313 PECOS PAC ID: 3971887167 Enrollment ID: O20170308000291 |
News Archive
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead product MycAssay™ Aspergillus for detection of Aspergillus DNA in serum.
Historically, health insurance covered mental health care differently than other medical care. Recent laws have begun bringing them into balance. ... Congress passed the Mental Health Parity and Addiction Equity Act (MHPAEA) in 2008. ... the MHPAEA applied to large group health plans, both fully and self-insured, and included a cost exemption.
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Deborah Marie Rambo, CRNA 149 Wilton Hill Rd, Columbia, SC 29212-2523 Ph: () - | Deborah Marie Rambo, CRNA 809 82nd Pkwy, Anesth Dept, Myrtle Beach, SC 29572-4607 Ph: (843) 692-1000 |
News Archive
Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC).
A new diagnostic tool that can predict whether a cancer patient would respond to immunotherapy treatment has been developed by scientists at the University of Bath.
Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead product MycAssay™ Aspergillus for detection of Aspergillus DNA in serum.
Historically, health insurance covered mental health care differently than other medical care. Recent laws have begun bringing them into balance. ... Congress passed the Mental Health Parity and Addiction Equity Act (MHPAEA) in 2008. ... the MHPAEA applied to large group health plans, both fully and self-insured, and included a cost exemption.
Six stages of engagement in treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) have been reported by researchers at Boston Medical Center based on a diverse study, inclusive of parents of predominantly racial and ethnic minority children with ADHD.
› Verified 2 days ago
Travis Mills, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2432 Hunters Trl, Myrtle Beach, SC 29588 Phone: 423-736-0357 | |
Patrick E Quinn, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Jane I Dickman, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Jean M. Vinski, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-692-1062 | |
Debra K Hamerski, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 7900 N Kings Hwy, Myrtle Beach, SC 29572 Phone: 843-449-3381 | |
Irina Walker, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 809 82nd Pkwy, Myrtle Beach, SC 29572 Phone: 843-602-2408 |